Molecules originating from living cells, including those of microorganisms, plants, or animals, and utilized for the treatment, diagnosis, or prevention of various diseases are known as biologics drugs. Oral biologics products such as etanercept (Enbrel), adalimumab (Humira), and abatacept (Orencia), refer to biological drugs taken from oral disease indications. These drugs are widely used in the treatment of various diseases such as plaque psoriasis, ulcerative colitis, diabetes, Crohn’s disease, etc. Moreover, the growth of the oral biologics market can be attributed to the rising incidences of autoimmune diseases such as ankylosing spondylitis, rheumatoid arthritis, and others. For instance, according to the estimates of the Arthritis Foundation (AF), the global prevalence of rheumatoid arthritis is 0.5 to 1% in developed countries.
The oral biologics market is expected to grow at a steady rate of around 22%. This is mainly due to the cost-effectiveness of biosimilars, loss of protection events of original drug manufacturers, strong product pipeline, company collaborations for research and development of new drugs, and increasing FDA approvals in major countries are some of the factors contributing to the growth of the market. For instance, in 2021, Amgen Inc., a biopharmaceutical company & Entera Bio Ltd. Entered into a research collaboration and license agreement to develop oral administration formulas of biologic drugs.
According to UnivDatos Market Insights (UMI)’ research report “Global Oral Biologics Market”, the market is expected to witness robust growth during the forecast period (2022-2028). This is mainly due to the prevalence of chronic diseases, increasing government initiatives, and technological advancements in research & development by major key players.
Ask for Sample Customization- https://univdatos.com/get-a-free-sample-form-php/?product_id=35388
Based on drug class, the market is segmented into glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, guanylate cyclase-c agonist, hormone, and others. Among them, the glucagon-like peptide 1 (GLP-1) receptor agonist category is expected to hold the major market share during the forecast period. This is mainly due to the rising product approvals, product launches, partnerships, collaborations, mergers & acquisitions by key players, and R&D activities are expected to drive the market growth over the forecast period. For instance, in December 2020, Entera Bio Ltd. announced that the U.S. Food Drug and Administration had revived the company’s Investigational New Drug (IND) application for EB613, orally delivered human parathyroid hormone (1-34) or PTH, for the treatment of osteoporosis patients.
Based on the disease indication, the market is categorized into diabetes, hyperoxaluria, acromegaly, irritable bowel syndrome (IBS), chronic idiopathic constipation (CIC), and others. Among these, the diabetes category held a significant share of the market in 2021. This is mainly due to the increasing prevalence of type 1 diabetes globally and the rising prevalence of obesity will drive the segmental growth during the forecast period. For instance, as per the International Diabetes Federation (IDF), around 1.2 million youngsters and youths have type 1 diabetes in 2021.
North America to witness extensive growth
For a better understanding of the market adoption of the oral biologics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to held a dominant share in the market. The major factors such as well-established healthcare infrastructure, and rising incidences of chronic diseases such as cancer, autoimmune diseases, diabetes, arthritis, Alzheimer’s disease, and chronic kidney disease will contribute to the growth of the market. For instance, according to GLOBOCAN 2020, the number of new cancer cases diagnosed was 2,281,658 in the U.S. in 2020. Furthermore, rising investment in research and development activities by the key industry players and an increasing pipeline of products & new product launches in the market are also driving the market growth.
According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the oral biologics market are Novo Nordisk A/S; Biocon; Oramed; Rani Therapeutics; EnteraBio Ltd.; AbbVie Inc.; Enteris BioPharma Inc.; Chiasma, Inc.; Allena Pharmaceuticals; Lilly.
“Global Oral Biologics Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.
Market Segmentation:
1. By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Recombinant Enzyme, Somatostatin Analogue, Guanylate Cyclase-C Agonist, Hormone, and Others)
2. By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS), Chronic Idiopathic Constipation (CIC), and Others)
3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
4. By Region (North America, Europe, Asia-Pacific, Rest of the World)
5. By Company (Novo Nordisk A/S; Biocon; Oramed; Rani Therapeutics; EnteraBio Ltd.; AbbVie Inc.; Enteris BioPharma Inc.; Chiasma, Inc.; Allena Pharmaceuticals; Lilly)
Key questions answered in the study:
1. What are the current and future trends of the global oral biologics market industry?
2. How the industry has been evolving in terms of drug class, disease indication, and distribution channel?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the global oral biologics market industry?
5. What is the customer orientation, purchase behavior, and expectations from the global oral biologics market suppliers across various region and countries?
For Detailed Analysis on the topic- https://univdatos.com/report/oral-biologics-market/
Table of Content:-
1 MARKET INTRODUCTION
2 RESEARCH METHODOLOGY OR ASSUMPTION
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 IMPACT OF COVID-19 ON THE ORAL BIOLOGICS MARKET
6 ORAL BIOLOGICS MARKET REVENUE, 2020-2028F
7 MARKET INSIGHTS BY DRUG CLASS
8 MARKET INSIGHTS BY DISEASE INDICATION
9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL
10 MARKET INSIGHTS BY REGION
11 ORAL BIOLOGICS MARKET DYNAMICS
12 ORAL BIOLOGICS MARKET OPPORTUNITIES
13 ORAL BIOLOGICS MARKET TRENDS
14 DEMAND AND SUPPLY-SIDE ANALYSIS
15 VALUE CHAIN ANALYSIS
16 PRICING ANALYSIS
17 STRATEGIC INSIGHTS
18 COMPETITIVE SCENARIO
19 COMPANY PROFILED
20 DISCLAIMER